Compounding-Specific Considerations Compounded GLP-1 medications are not tested for bioequivalence against brand-name versions
The journey from high-risk HLA alleles and viral mimicry to targeted destruction of pancreatic beta cells highlights a disease process that is now decipherable at the mechanistic level
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia
Retatrutide is an investigational triple hormone receptor agonist that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously
Overeating may cause you to feel full, possibly leading to symptoms like abdominal pain, bloating, nausea, acid reflux, sleepiness, and vomiting
Epidemiologic studies have consistently shown a mortality advantage among patients with hematocrits in the 30% to 36% range, and the NKF-DOQI Work Group on Anemia Management recommended a target hematocrit of 33% to 36% based on the expert panels' detailed literature review